# Robert J. Jones

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-j-jones/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,912 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 70 |
| i10-index | 198 |
| OpenAlex ID | https://openalex.org/A5048796030 |
| ORCID iD | https://orcid.org/0000-0002-2904-6980 |
| Works | 432 |

## Researcher papers

- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer](https://scholariq.org/papers/dna-repair-defects-and-olaparib-in-metastatic-prostate-cancer/)
- [Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial](https://scholariq.org/papers/addition-of-docetaxel-zoledronic-acid-or-both-to-first-line-long-term-hormone/)
- [Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/pazopanib-versus-sunitinib-in-metastatic-renal-cell-carcinoma/)
- [Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy](https://scholariq.org/papers/abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy/)
- [Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial](https://scholariq.org/papers/radiotherapy-to-the-primary-tumour-for-newly-diagnosed-metastatic-prostate/)
- [Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/talazoparib-plus-enzalutamide-in-men-with-first-line-metastatic-castration/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.